Alefacept in the Treatment of Psoriatic Nail Disease: A Proof of Concept Study

April 2006 | Volume 5 | Issue 4 | Original Article | 339 | Copyright © 2006

Charles A. Parrish MD, Jenny O. Sobera MD, Courtney M. Robbins MD, Wendy C. Cantrell CRNP, Renee A. Desmond DVM PhD, Boni E. Elewski MD


Nail psoriasis can be debilitating and as therapeutic options are limited, it can be notoriously difficult to treat. As there are many new medications currently undergoing clinical trials in psoriasis, questions have arisen concerning the effectiveness of these new therapies with regard to psoriatic nail disease. We present the results of a prospective, open-label, proof of concept study to determine the efficacy and safety of alefacept in subjects with moderate to severe nail psoriasis.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Related Articles